The Astellas Institute for Regenerative Medicine (AIRM) has signed a Master Collaborative Services Agreement (MSA) with Exopharm, through which the partners plan to carry out initial lab work, with the goal for Astellas of deciding whether exosome products can be added to its pipeline. That work will begin at Exopharm's laboratories in Melbourne, Australia, when the partners seek to purify exosomes derived from two proprietary AIRM cell line by applying Exopharm's Ligand-based Exosome Affinity Purification (LEAP™) technology platform . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge